+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mental Disorders Drugs Market Research Reports

mGlu 2/3 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

mGlu 2/3 Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
mGlu 2/3/5 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

mGlu 2/3/5 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Serotonin Transporter Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin Transporter Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
D Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

D Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Sigma Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Sigma Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Serotonin receptor 2 angonist - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin receptor 2 angonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
From
United States and Japan LATUDA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States and Japan LATUDA Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Japan, United States Japan, United States
From
United States VRAYLAR Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States VRAYLAR Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • United States
From
SPRAVATO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

SPRAVATO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • September 2022
  • 30 Pages
  • Global
From
Major Depressive Disorder - Epidemiology Forecast - 2032 - Product Thumbnail Image

Major Depressive Disorder - Epidemiology Forecast - 2032

  • Report
  • June 2022
  • 148 Pages
  • Global
From
From
Postpartum Depression - Epidemiology Forecast to 2032 - Product Thumbnail Image

Postpartum Depression - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
General Anxiety Disorder (GAD) - Epidemiology Forecast to 2032 - Product Thumbnail Image

General Anxiety Disorder (GAD) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Loading Indicator

The Mental Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat mental health conditions. These drugs are used to treat a wide range of mental health issues, including depression, anxiety, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The market is highly competitive, with many companies vying for market share. The Mental Disorders Drugs market is driven by the increasing prevalence of mental health issues, as well as the growing demand for effective treatments. Additionally, advances in technology and research have enabled the development of more effective drugs. Some of the major players in the Mental Disorders Drugs market include Pfizer, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, and AstraZeneca. These companies are engaged in the development and production of drugs used to treat mental health conditions. Additionally, they are involved in research and development activities to develop new drugs and treatments. Show Less Read more